



## PRESS RELEASE

### Crucell Announces Large Scale Quinvaxem™ Vaccinations in Ethiopia

**Leiden, The Netherlands, March 23, 2007** – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that children in the Ethiopian capital Addis Ababa, have received their first dose of Quinvaxem™ vaccine. Ethiopia is the most populous GAVI Alliance supported country to date to have *Haemophilus influenzae* type b (Hib) immunization included in its routine immunization programme. Quinvaxem™ is a new fully-liquid pentavalent vaccine which protects against five important childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B and *Haemophilus influenzae* type b (Hib). Hib is a significant cause of life-threatening pneumonia and meningitis in children under 5 years of age with pneumonia being the leading cause of under-5 mortality.

Quinvaxem™ has now been introduced in several Latin American and African countries vaccination programs supported and co-financed by supranational organizations.

"The multiple year contracts that the supranational organizations have granted to Crucell, underline Crucell's place as a leading supplier of such important vaccines. Quinvaxem™ is the first internationally available fully-liquid vaccine containing these five life saving antigens and it will make a significant contribution to children's vaccination programs in the developing world," said Crucell's President and CEO, Dr. Ronald H.P. Brus. "Quinvaxem™ will be an important contributor to the company's 2007 total revenues, being estimated in excess EURO 200 million and our objective to be cash neutral in 2007."

Quinvaxem™ was co-developed with Novartis and is produced in Crucell's laboratories in South Korea. Current demand for the vaccine exceeds 50 million doses. The total market potential is estimated to be 150 million doses per year in 3 to 4 years.

#### **About Crucell**

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland,



Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people.  
For more information, please visit [www.crucell.com](http://www.crucell.com).

**Forward-looking statements**

*This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).*

**For further information please contact:**

**Crucell N.V.**

Leonard Kruimer  
Chief Financial Officer  
Tel. +31-(0)71-524 8722  
[Leonard.Kruimer@crucell.com](mailto:Leonard.Kruimer@crucell.com)

**For Crucell in the US:**

**Redington, Inc.**  
Thomas Redington  
Tel. +1 212-926-1733  
[tredington@redingtoninc.com](mailto:tredington@redingtoninc.com)

Barbara Mulder  
Director Corporate Communications  
Tel: 31-(0) 71 524 8718  
[barbara.mulder@crucell.com](mailto:barbara.mulder@crucell.com)